Abstract:Importance Cognitive impairment contributes significantly to clinical outcome and level of function in individuals with psychotic disorders. These impairments are present already at psychosis onset at a group level; however, the question of heterogeneity in cognitive function among patients has not been systematically investigated. Objective To provide an updated quantification of cognitive impairment at psychosis onset before patients receive potentially confounding antipsychotic treatment, and to investigate variability in cognitive function compared with healthy controls. Data Sources In this systematic review and meta-analysis, PubMed articles were searched up to September 15, 2022. Study Selection Original studies reporting data on cognitive function in antipsychotic drug–naive patients with first-episode psychosis (FEP) were included. Data Extraction and Synthesis Data were independently extracted by 2 researchers. Cognitive tasks were clustered according to 6 domains of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery and the domain of executive function. Random-effects model meta-analyses of mean differences and coefficient of variation ratios (CVRs) were performed, as well as meta-regressions, assessment of study quality, and publication bias. Main Outcomes and Measures The main outcome measure was Hedges g for mean differences in cognition and CVR for within-group variability. Results Fifty studies were included in the analysis with a total of 2625 individuals with FEP (mean [SD] age, 25.2 [3.6] years, 60% male; 40% female) and 2917 healthy controls (mean [SD] age, 26.0 [4.6]; 55% male; 45% female). In all cognitive domains, the FEP group displayed significant impairment compared with controls (speed of processing: Hedges g = −1.16; 95% CI, −1.35 to −0.98; verbal learning: Hedges g = −1.08; 95% CI, −1.28 to −0.88; visual learning: Hedges g = −1.05; 95% CI, −1.27 to −0.82; working memory: Hedges g = −1.04; 95% CI, −1.35 to −0.73; attention: Hedges g = −1.03; 95% CI, −1.24 to −0.82; reasoning/problem solving: Hedges g = −0.90; 95% CI, −1.12 to −0.68; executive function: Hedges g = −0.88; 95% CI, −1.07 to −0.69). Individuals with FEP also exhibited a larger variability across all domains (CVR range, 1.34-1.92). Conclusions and Relevance Results of this systematic review and meta-analysis identified cognitive impairment in FEP before the initiation of antipsychotic treatment, with large effect sizes. The high variability within the FEP group suggests the need to identify those individuals with more severe cognitive problems who risk worse outcomes and could benefit the most from cognitive remediation.

Cognitive Impairment in First-Episode Negative Symptom–Dominant Psychosis

Cognitive Impairments in Drug-Naive Patients with First-Episode Negative Symptom-Dominant Psychosis

Relationship Between Negative Symptoms and Neurocognitive Functions in Adolescent and Adult Patients with First-Episode Schizophrenia

The clinical symptoms and neurocognitive impairment of first-episode deficit and nondeficit subtype of schizophrenia

Cognitive impairment in patients with first-episode schizophrenia and the correlation of different mental symptoms

Association of negative symptoms with cognitive impairment in Chinese Han patients with chronic schizophrenia

Cognitive Impairment and Diminished Neural Responses Constitute a Biomarker Signature of Negative Symptoms in Psychosis

Cognitive Function and Variability in Antipsychotic Drug–Naive Patients With First-Episode Psychosis

Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia

Die bedeutung der negativsymptomatik für kognitive defizite bei patienten mit erstmanifestation einer schizophrenie

Cognitive Inflexibility Predicts Negative Symptoms Severity in Patients with First-Episode Psychosis: A 1-Year Follow-Up Study

Contingent Negative Variation in First Episode Deficit and Non-Deficit Schizophrenia:A Comparative Study

[Clinical and psychometric characteristics of cognitive and negative disorders in schizophrenia]

Cognitive Deficits in Subjects at Risk for Psychosis, First-Episode and Chronic Schizophrenia Patients.

Cognitive Impairments in First-Episode Drug-Naive and Chronic Medicated Schizophrenia: MATRICS Consensus Cognitive Battery in a Chinese Han Population.

Social cognition and neurocognition in first-episode bipolar disorder and psychosis: The effect of negative and attenuated positive symptoms

Persistent Negative Symptoms in First Episode Patients with Schizophrenia: Results from the European First Episode Schizophrenia Trial

Relationships Between Dorsolateral Prefrontal Cortex Metabolic Change and Cognitive Impairment in First-Episode Neuroleptic-Naive Schizophrenia Patients.

Gender Differences of Neurocognitive Functioning in Patients with First-Episode Schizophrenia in China.

Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables

Meta-analysis of Cognitive Function in Chinese First-Episode Schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment